Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma
Martenson, James A., Haddock, Michael G. , Novotny, Paul J. , Miller, Robert C. , Rosen, Charles B. , Sio, Terence T. , Gores, Gregory J. , Alberts, Steven R. , Heimbach, Julie K.

American Journal of Clinical Oncology | June 12, 2014 | Volume: 39 | Issue: 3 | Pages: 271-275

10.1097/coc.0000000000000056 | PMID 24921218 Get It

Objectives: The aim of this was to determine survival after starting neoadjuvant therapy for patients who became ineligible for orthotopic liver transplantation (OLT). Methods and Materials: Since January 1993, 215 patients with unresectable cholangiocarcinoma began treatment with planned OLT. Treatment included external-beam radiation therapy (EBRT) with fluorouracil, bile duct brachytherapy, and postradiotherapy fluorouracil or capecitabine before OLT. Adverse findings at the staging operation, death, and other factors precluded OLT in 63 patients (29%), of whom 61 completed neoadjuvant chemoradiation. Results: By October 2012, 56 (89%) of the 63 patients unable to undergo OLT had died. Twenty-two patients (35%) became ineligible for OLT before the staging operation, 38 (60%) at the staging operation, and 3 (5%) after staging. From the date of diagnosis, median overall survival was 12.3 months. Survival was 17% at 18 months and 7% at 24 months. Median survival after fallout was 6.8 months. Median survival after the staging operation was 6 months. Two patients lived for 3.7 and 8.7 years before dying of cancer or liver failure caused by persistent biliary stricture at the site of the original cancer, respectively. Univariate analysis showed that time from diagnosis to fallout correlated with overall survival (P=0.04). Conclusions: In highly selected patients initially suitable for OLT, the mortality rate for cholangiocarcinoma was high in patients who became ineligible for OLT. Their survival, however, was comparable to expected survival for patients with locally advanced or metastatic disease treated with nontransplant therapies. The most common reason for patient fallout was adverse findings at the staging operation.
Ten Important Elements for Observational Studies in Primary Care and Community Health
Rohrer, James E.

Journal of Primary Care & Community Health | June 12, 2014 | Volume: 5 | Issue: 3 | Pages: 158-159

10.1177/2150131914538562 | PMID 24924684 Get It

Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study
Shi, Qian , Louvet, Christophe , Everson, Richard B., Kellner, Udo, Clancy, Thomas E. , Pipas, J. Marc , Resnick, Murray B. , Meyers, Michael O. , Wu, Tsung‐Teh, Huntsman, David G. , Validire, Pierre , Farooq, Umar , Pavey, Emily S., Beaudry, Guillaume, Haince, Jean-François, Fradet, Yves , Sargent, Daniel J. , Gill, Sharlene , Farooq, Umar , Shi, Qian , Fradet, Yves

Clinical Cancer Research | June 12, 2014 | Volume: 20 | Issue: 16 | Pages: 4361-4369

10.1158/1078-0432.ccr-13-2659 | PMID 24919572 Get It

Abstract Purpose: Recurrence risk assessment to make treatment decisions for early-stage colon cancer patients is a major unmet medical need. The aim of this retrospective multicenter study was to evaluate the clinical utility of guanylyl cyclase C (GCC) mRNA levels in lymph nodes on colon cancer recurrence. Methods: The proportion of lymph nodes with GCC-positive mRNA (LNR) was evaluated in 463 untreated T3N0 patients, blinded to clinical outcomes. One site's (n = 97) tissue grossing method precluded appropriate lymph node assessment resulting in post hoc exclusion. Cox regression models tested the relationship between GCC and the primary endpoint of time to recurrence. Assay methods, primary analyses, and cut points were all prespecified. Results: Final dataset contained 366 patients, 38 (10%) of whom had recurrence. Presence of four or more GCC-positive lymph nodes was significantly associated with risk of recurrence [hazard ratio (HR) = 2.46, 95% confidence interval (CI), 1.07–5.69, P = 0.035], whereas binary GCC LNR risk class (HR = 1.87, 95% CI, 0.99–3.54, P = 0.054) and mismatch repair (MMR) status (HR = 0.77, 95% CI, 0.36–1.62, P = 0.49) were not. In a secondary analysis using a 3-level GCC LNR risk group classification of high (LNR > 0.20), intermediate (0.10 < LNR ≤ 0.20), and low (LNR ≤ 0.10), high-risk patients had a 2.5 times higher recurrence risk compared with low-risk patients (HR = 2.53, 95% CI, 1.24–5.17, P = 0.011). Conclusions: GCC status is a promising prognostic factor independent of traditional histopathology risk factors in a contemporary population of patients with stage IIa colon cancer not treated with adjuvant therapy, but GCC determination must be performed with methodology adapted to the tissue procurement and fixation technique. Clin Cancer Res; 20(16); 4361–9. ©2014 AACR.
External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort
Chen, Li-Mei, Chang, Myron, Dai, Yunfeng , Chai, Karl X., Dyrskjøt, Lars , Sänchez‐Carbayo, Marta, Szarvas, Tibor , Zwarthoff, Ellen C. , Lokeshwar, Vinata B. , Jerónimo, Cármen , Parker, Alexander S. , Ross, Shanti, Borre, Michael , Ørntoft, Torben F., Jaeger, T., Beukers, Willemien, López, Luis E., Henrique, Rui , Urquidi, Virginia, Goodison, Steve , Rosser, Charles J. , Chen, Li‐Mei , Young, Paul R.

Cancer Epidemiology, Biomarkers & Prevention | June 12, 2014 | Volume: 23 | Issue: 9 | Pages: 1804-1812

10.1158/1055-9965.epi-14-0029 | PMID 24920641 Get It

Abstract Background: Because of the faltering sensitivity and/or specificity, urine-based assays currently have a limited role in the management of patients with bladder cancer. The aim of this study was to externally validate our previously reported protein biomarker panel from multiple sites in the United States and Europe. Methods: This multicenter external validation study included a total of 320 subjects (bladder cancer = 183). The 10 biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SDC1, and SERPINE1) were measured using commercial ELISA assays in an external laboratory. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values. Results: Utilizing the combination of all 10 biomarkers, the area under the ROC for the diagnostic panel was noted to be 0.847 (95% confidence interval, 0.796–0.899), outperforming any single biomarker. The multiplex assay at optimal cutoff value achieved an overall sensitivity of 0.79, specificity of 0.79, positive prediction value of 0.73, and negative prediction value of 0.84 for bladder cancer classification. Sensitivity values of the diagnostic panel for high-grade bladder cancer, low-grade bladder cancer, muscle invasive bladder cancer, and non-muscle invasive bladder cancer were 0.81, 0.90, 0.95, and 0.77, respectively. Conclusions: Urinary levels of the biomarker panel enabled discrimination of patients with bladder cancer and controls, and the levels of biomarker subsets were associated with advancing tumor grade and stage. Impact: If proven to be reliable, urinary diagnostic biomarker assays can detect bladder cancer in a timely manner such that the patient can expect improvements in overall survival and quality of life. Cancer Epidemiol Biomarkers Prev; 23(9); 1804–12. ©2014 AACR.
Successful Treatment of Subungual Fibromas of Tuberous Sclerosis With Topical Rapamycin
Muzic, John G. , Kindle, Scott A., Tollefson, Megha M.

JAMA Dermatology | June 11, 2014 | Volume: 150 | Issue: 9 | Pages: 1024

10.1001/jamadermatol.2014.87 | PMID 24919623 Get It

Treatment of Gonococcal Infection: When One Drug Is Not Enough
Kransdorf, Lisa N. , Kling, Juliana M. , Mayer, Anita P. , Kransdorf, Lisa N , Kling, Juliana M

Journal of Women's Health | June 11, 2014 | Volume: 23 | Issue: 7 | Pages: 627-628

10.1089/jwh.2014.4820 | PMID 24918549 Get It

The sHunt for Better Breathing in Heart Failure With Preserved Ejection Fraction
Borlaug, Barry A. , Borlaug, Barry A

European Journal of Heart Failure | June 11, 2014 | Volume: 16 | Issue: 7 | Pages: 709-711

10.1002/ejhf.120 | PMID 24920438 Get It

Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder
Stelling, Brianna E. Vaa , Price, Katharine A. , Vaa, Brianna, Kohli, Manish , Swetz, Keith Mark, Swetz, Keith M.

BMJ Case Reports | June 11, 2014 | Volume: 2014 | Issue: No issue available | Pages: bcr2013200137

10.1136/bcr-2013-200137 | PMID 24920508 Get It

Transitional cell carcinoma of the bladder (TCC) represents nearly 90% of genitourinary malignancies and typically presents with locally invasive symptoms. Metastasis to the central nervous system (CNS) is uncommon occurring in <5% of patients. When present, metastatic lesions are typically solid, isolated and located in the cerebrum. We report a case of a patient with a history of TCC who presented with lethargy and ataxia and was found to have a solitary cystic cerebellar lesion consistent with metastatic disease. Unfortunately, the prognosis for patients with TCC and CNS metastases is poor. Treatment options include debulking surgery, whole brain radiation, stereotactic radiosurgery and chemotherapy. Unfortunately, treatment may not appreciably extend survival and care is often supportive in previously reported cases. Though uncommon, TCC can metastasise to the CNS and should be considered in the differential diagnosis of patients, particularly those who were treated with aggressive surgery or combination chemotherapy previously.
Syphilitic Alopecia
Wetter, David A. , Henderson, Gregory P.

Internal Medicine | June 11, 2014 | Volume: 52 | Issue: 17 | Pages: 2013-2013

10.2169/internalmedicine.52.0452 | PMID 23995009 Get It

Overdiagnosis of gastro‐esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community
Pleyer, Christopher , Bittner, H, Locke, G. Richard, Choung, Rok Seon , Zinsmeister, Alan R., Schleck, Cathy D. , Herrick, Linda M., Talley, Nicholas J. , Choung, Rok Seon

Neurogastroenterology & Motility | June 11, 2014 | Volume: 26 | Issue: 8 | Pages: 1163-1171

10.1111/nmo.12377 | PMID 24916517 Get It

AbstractBackgroundThere is symptom overlap between gastro‐esophageal reflux disease (GERD) and functional dyspepsia (FD). We aimed to test the hypothesis that FD cases are now more likely mislabeled as GERD.MethodsIn subjects from Olmsted County, MN seen at Mayo Clinic: (i) Investigation of GERD and FD diagnosis rates between 1985 and 2009. (ii) Assessment of survey‐based upper gastrointestinal symptoms between 1988 and 2009. (iii) Analysis of patients reporting GERD and/or FD symptoms and subsequently receiving a consistent diagnosis of GERD and/or FD during a medical encounter. (iv) Assess the association between PPI use and GERD and/or FD symptoms and between actual diagnoses received.Key Results(i) Yearly GERD diagnosis rates rose between 1985 and 2009 (325–1866 per 100 000). FD diagnosis rates rose from 45 in 1985, to 964 in 1999 but decreased to 452 per 100 000 in 2009. (ii) Reported GERD symptoms did not significantly change between three survey waves in the years 1988–2009 (p = 0.052), whereas FD symptoms slightly increased (p = 0.01). (iii) 62.9% of subjects reporting GERD symptoms received a GERD diagnosis, however only 12.5% of subjects reporting FD symptoms received a FD diagnosis. (iv) PPI use was associated with documented GERD diagnosis (p < 0.001), however there was no significant association between GERD symptoms and PPI use (p = 0.078).Conclusions & InferencesWe have found evidence supporting a systematic bias away from diagnosing FD, favoring a GERD diagnosis.